iRadimed Corporation $IRMD is Nine Ten Capital Management LLC's 6th Largest Position

Key Points

• Nine Ten Capital Management cut its iRadimed stake by 23.3% in the second quarter, but the stock remains its sixth-largest holding at 7.6% of assets. Institutional investors collectively own 92.34% of IRMD.
• iRadimed exceeded quarterly expectations, reporting $0.46 in EPS versus a $0.44 consensus and revenue of $20.47 million versus $20.35 million expected. Management guided fiscal 2026 EPS to $2.09–$2.24.
• Analyst sentiment remains positive but moderated, with an average “Moderate Buy” rating and a $120 price target, while shares recently opened at $84.40. The company also pays a quarterly dividend of $0.20, yielding approximately 0.9% annually.

Nine Ten Capital Management LLC trimmed its holdings in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) by 23.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 256,562 shares of the medical equipment provider's stock after selling 77,926 shares during the quarter. iRadimed accounts for approximately 7.6% of Nine Ten Capital Management LLC's holdings, making the stock its 6th biggest holding. Nine Ten Capital Management LLC owned approximately 2.01% of iRadimed worth $24,517,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. IFP Advisors Inc lifted its holdings in shares of iRadimed by 264.7% in the 2nd quarter. IFP Advisors Inc now owns 569 shares of the medical equipment provider's stock worth $54,000 after acquiring an additional 413 shares during the last quarter. California State Teachers Retirement System raised its position in iRadimed by 12,018.2% in the 2nd quarter. California State Teachers Retirement System now owns 954,549 shares of the medical equipment provider's stock worth $91,217,000 after purchasing an additional 946,672 shares during the period. Punch & Associates Investment Management Inc. bought a new stake in iRadimed in the second quarter worth about $1,911,000. Bank of America Corp DE purchased a new position in shares of iRadimed during the second quarter valued at approximately $1,834,000. Finally, Man Group plc bought a new position in shares of iRadimed during the second quarter valued at approximately $1,514,000. Institutional investors own 92.34% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on IRMD. Wall Street Zen lowered iRadimed from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Weiss Ratings downgraded iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $120.00.

iRadimed Stock Performance

Shares of NASDAQ IRMD opened at $84.40 on Wednesday. iRadimed Corporation has a 52-week low of $67.84 and a 52-week high of $107.90. The firm has a market capitalization of $1.08 billion, a price-to-earnings ratio of 47.15 and a beta of 0.89. The stock has a 50 day moving average price of $91.77 and a 200 day moving average price of $93.37.

iRadimed (NASDAQ:IRMD - Get Free Report) last released its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. The company had revenue of $20.47 million during the quarter, compared to analyst estimates of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. Analysts forecast that iRadimed Corporation will post 1.98 earnings per share for the current year.

iRadimed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were paid a $0.20 dividend. The ex-dividend date was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. iRadimed's dividend payout ratio (DPR) is 44.69%.

Insider Buying and Selling

In other news, Director Monty K. Allen sold 1,419 shares of the company's stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $86.41, for a total transaction of $122,615.79. Following the transaction, the director owned 19,581 shares in the company, valued at $1,691,994.21. This represents a 6.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 34.60% of the company's stock.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.